Kodiak Sciences Q1 EPS Forecast Reduced by HC Wainwright

Kodiak Sciences Inc. (NASDAQ:KOD) – Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Kodiak Sciences in a report released on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.94) per share for the quarter, down from their previous estimate of ($0.75). HC Wainwright currently has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($3.19) EPS, FY2028 earnings at ($1.94) EPS, FY2029 earnings at $0.19 EPS and FY2030 earnings at $3.05 EPS.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Tuesday, March 31st. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02).

A number of other equities analysts have also issued reports on KOD. UBS Group boosted their target price on shares of Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kodiak Sciences presently has an average rating of “Moderate Buy” and an average target price of $35.43.

Kodiak Sciences Price Performance

Shares of KOD stock opened at $40.63 on Friday. Kodiak Sciences has a 12 month low of $1.92 and a 12 month high of $45.60. The firm has a market cap of $2.51 billion, a PE ratio of -9.41 and a beta of 2.39. The stock has a 50 day moving average of $26.37 and a 200-day moving average of $22.93.

Institutional Investors Weigh In On Kodiak Sciences

Several large investors have recently modified their holdings of the stock. Boone Capital Management LLC bought a new position in shares of Kodiak Sciences during the 3rd quarter worth approximately $11,719,000. TD Asset Management Inc bought a new position in shares of Kodiak Sciences during the third quarter valued at $992,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Kodiak Sciences during the 3rd quarter worth about $488,000. Panagora Asset Management Inc. increased its position in shares of Kodiak Sciences by 28.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock worth $489,000 after purchasing an additional 29,113 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Kodiak Sciences during the 3rd quarter valued at about $228,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences News Summary

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: HC Wainwright keeps a “Buy” rating and a $58 price target on KOD despite trimming earnings forecasts — a sign that at least one major broker still sees meaningful upside beyond near‑term losses. MarketBeat Kodiak page
• Neutral Sentiment: Healio reports that “Zenkuda” showed superiority to sham in a Phase 3 diabetic retinopathy study. Investors will evaluate whether this readout affects Kodiak directly (if Zenkuda is related to Kodiak’s pipeline) or if it changes the competitive landscape in retinal therapeutics. Zenkuda Phase 3 readout
• Neutral Sentiment: Kodiak issued a corporate release summarizing recent business highlights and its fourth‑quarter and full‑year 2025 financial results; investors should read the filing for cash runway, revenue/expense items and any pipeline milestone updates that could materially affect valuation. Kodiak Q4/FY2025 results
• Negative Sentiment: Multiple analyst teams (HC Wainwright and Lifesci Capital) cut near‑term and multi‑year EPS estimates in reports issued April 1 — revisions include larger expected losses for Q1–Q4 2026 and downgraded FY2026 and out‑year forecasts (examples: HC Wainwright moved FY2026 to about ($3.56) EPS; Lifesci trimmed FY2026 toward ($2.52) EPS). Those downgrades increase short‑term downside risk as they raise expectations for continued operating losses and may push markets to reprice growth/timing assumptions. Analyst revision summaries

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.